CAMBA, a New Synthesized and Promising Protector against STZ-Induced Diabetic Complications in Rats

Abstract

CAPE, one of the most active compounds in propolis, is the perfect illustration of a natural compound exhibiting diverse biological activities. However, rapid decomposition by esterase leads to its low bioavailability in vivo. The aim of the present study is to synthesis and investigates the antioxidant and protective activities of novel derivative of caffeic acid, CAMBA against STZ-induced diabetic complications in diabetic rats. Since amide is more resistant to esterase enzyme. CAMBA was synthesized by reacting the amino group of methyl anthranilate with caffeic acid in the presence of PCl 3 . Diabetic rats was induced by injection of STZ (55 mg/kg, i.p.) and diabetes was confirmed 48 h after induction, and then allowed for 7 days to stabilize blood glucose level. CAMBA (25 and 50 mg/kg b.w daily for 28 days) treated diabetic rats significantly reduced elevated blood glucose, TC, TG, atherogenic index, LDL-c, vLDL-c, hepatic, renal and cardiac TBARs and HP. The treatment also resulted in improved the insulin and insulin resistance and significantly increased serum HDL-c and GSH, SOD, CAT and GPx in the liver, kidney and heart of diabetic rats. The results clearly suggest that CAMBA treated group may effectively normalize the impaired antioxidant status in streptozotocin induced diabetes than the glibenclamide-treated groups. CAMBA exerted rapid protective effects against lipid peroxidation by scavenging of free radicals by reducing the risk of diabetic complications. Taken together, CAMBA has potential as an antioxidant agent for diabetes and deserves clinical trial in the near future as an adjuvant therapy in diabetic patients.